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Abstract
Accumulated evidence implies that hepatitis C virus (HCV) infects not only the liver but also the immune system. A
lymphocyte-specific CD5 molecule was recently identified as essential for infection of T cells with native, patient-derived
HCV. To assess whether the proposed hepatocyte receptors may also contribute to HCV lymphotropism, expression of
scavenger receptor-class B type 1 (SR-B1), claudin-1 (CLDN-1), claudin-6 (CLDN-6), occludin (OCLN), CD5 and CD81 was
examined by real-time RT-PCR and the respective proteins quantified by immunoblotting in HCV-prone and resistant T cell
lines, peripheral blood mononuclear cells (PBMC), primary T cells and their subsets, and compared to hepatoma Huh7.5 and
HepG2 cells. SR-B1 protein was found in T and hepatoma cell lines but not in PBMC or primary T lymphocytes, CLDN-1 in
HCV-resistant PM1 T cell line and hepatoma cells only, while CLDN-6 equally in the cells investigated. OCLN protein occurred
in HCV-susceptible Molt4 and Jurkat T cells and its traces in primary T cells, but not in PBMC. CD5 was displayed by HCV-
prone T cell lines, primary T cells and PBMC, but not by non-susceptible T and hepatoma cell lines, while CD81 in all cell
types except HepG2. Knocking-down OCLN in virus-prone T cell line inhibited HCV infection, while de novo infection
downregulated OCLN and CD81, and upregulated CD5 without modifying SR-B1 expression. Overall, while no association
between SR-B1, CLDN-1 or CLDN-6 and the susceptibility to HCV was found, CD5 and CD81 expression coincided with virus
lymphotropism and that of OCLN with permissiveness of T cell lines but unlikely primary T cells. This study narrowed the
range of factors potentially utilized by HCV to infect T lymphocytes amongst those uncovered using laboratory HCV and
Huh7.5 cells. Together with the demonstrated role for CD5 in HCV lymphotropism, the findings indicate that virus utilizes
different molecules to enter hepatocytes and lymphocytes.
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Introduction
Hepatitis C virus (HCV) is a positive single stranded RNA virus
that occurs as a symptomatic chronic infection in more than 170
million people. This infection represents a major health problem
worldwide despite significant advancement in blood screening
techniques [1,2]. Currently, there are no vaccines preventing
HCV infection, however new therapies show a significantly
improved antiviral potency and augmented rates of HCV
elimination, as measured by the detection of circulating HCV
RNA by the presently available clinical assays [3–5]. Efforts to
establish a robust HCV culture system have succeeded by
transfecting human hepatoma Huh7 cells with a full-length
HCV genome derived from a Japanese patient with fulminant
hepatitis C (JFH-1), resulting in secretion of infectious HCV JFH-1
particles (HCVcc) [6–8]. This infection model and other HCV
surrogate systems, such as HCV pseudoparticles (HCVpp) [9,10],
were applied to identify and/or to confirm molecules previously
proposed to mediate HCV infection of hepatoma Huh7 cells and
related cells lines which are expected to mimic normal human
hepatocytes. As a result, tetraspanin CD81 [11], glycosaminogly-
cans [12], scavenger receptor class B type1 (SR-B1) [9,13], and the
tight junction (TJ) proteins such as claudin-1 (CLDN-1) [14],
occludin (OCLN) [15,16], and other molecules, such as epidermal
growth factor receptor and ephrin receptor A2 [17] have been
proposed as receptors determining HCV tropism to human
hepatocytes. However, it remains uncertain to what degree these
models and the molecules identified reflect events occurring in
in vivo infection of hepatocytes with native virus.
Accumulated experimental and clinical evidence indicate that
HCV infects not only hepatocytes but also cells in extrahepatic
compartments, particularly those in the immune and the central
nervous systems [18,19]. In regard to infection of immune cells,
HCV replication was shown in circulating T and B lymphocytes
and monocytes from patients with symptomatic chronic as well as
silently progressing persistent infections [20,21]. The ex vivo
susceptibility of primary T lymphocytes and certain T cell lines,
such as Molt4 and Jurkat, to infection with native, patient-derived
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HCV and the ability of these cells to support the entire cycle of
HCV replication in culture have also been shown [22–25]. The
propensity of HCV to infect the host’s immune system is consistent
with a significantly greater prevalence of lymphoproliferative
disorders, such as mixed cryoglobulinemia and non-Hodgkin’s
lymphoma, in patients infected with HCV [26–30]. In contrast to
the several candidate receptors considered to be mediators of
HCV hepatotropism, factors determining HCV lymphotropism
are just being recognized. In this regard, a lymphocyte-specific
CD5 glycoprotein, belonging to the scavenger receptor cysteine-
rich family, has been recently identified to be essential for infection
of human T lymphocytes with native, patient-derived HCV [25].
A contribution of CD81 to infection of T cells by the patient-
derived virus has also been shown [23–25]. In the current study,
the expression of SR-B1, CLDN-1, CLDN-6 and OCLN, in
addition to CD5 and CD81, in HCV-prone and resistant T cell
lines and in peripheral blood mononuclear cells (PBMC) and
PBMC-derived primary T lymphocytes was investigated to assess
whether they may contribute to infection of lymphocytes with
authentic, patient-derived HCV and to compare their expression
with that in JFH-1 strain-prone hepatoma Huh7.5 and JFH-1-
resistant HepG2 cell lines. Based on the results of this comparative
analysis, involvement of OCLN in facilitation of infection in T cell
lines prone to naturally occurring virus was examined.
Results
Molt4 and Jurkat T Cells and Primary T Lymphocytes
Demonstrate Comparable Susceptibility to Infection with
Native HCV
Primary human T cells, PBMC from which the T cells were
derived, and T cell lines, including HCV-prone Molt4 and Jurkat
cells and HCV-resistant PM1 and CEM cells [25], were exposed
to patient-derived HCV and subsequently examined for expres-
sion of HCV RNA positive and replicative strands. As the results
showed (Fig. 1), Molt4 and Jurkat T cells displayed HCV RNA
positive strand at levels comparable to those detected in primary T
lymphocytes and PBMC (P=0.6), while CEM cells where entirely
nonreactive and PM1 cells only occasionally (i.e., in one of 3
experiments) expressed the strand at a very low level (Fig. 1A).
These results were compatible to those previously reported,
including the observation that PM1 cells can become prone to
HCV infection when activated [25].
Similarly as HCV RNA positive strand, the negative strand was
detected at comparable levels in Molt4, Jurkat, primary T cells
and PBMC following exposure to the same HCV inoculum.
Figure 1B shows an example of the strand identification in the cells
obtained in one of 3 experiments performed. In contrast, PM1 and
CEM cells, which have been identified to be naturally resistant to
infection with native HCV, were HCV RNA replicative strand
nonreactive.
Uniformly High Expression of CD81 and Aberrant
Expression of SR-B1 Characterize T Cells Either Prone or
Resistant to HCV Infection
Comparative analysis revealed that CD81 was ubiquitously
expressed at similarly high levels in primary T cells, their CD4+
and CD8+ subsets and in all T cell lines investigated, independent
of whether they were or were not susceptible to infection with
HCV, as well as in Huh7.5, PHH, and control HEK-293 cells
(Fig. 2A). The exception was HepG2 cells. Thus, CD81 mRNA
levels typically ranged between 106 and 107 copies/mg total RNA,
but HepG2 cells transcribed the gene at about 103-fold lower levels
(Fig. 2A).
Both HCV-susceptible and resistant T cell lines expressed SR-
B1 at significantly higher (P=0.007) levels than primary T cells,
purified CD4+ or CD8+ T lymphocyte subsets or total PBMC. In
general, primary T cells, their subsets and PBMC transcribed SR-
B1 at the mean level of 3.961036 SEM 628 copies/mg total RNA,
which was 2 to 3-fold lower than that detected in the T cell lines
(Fig. 2B). Moreover, HCV-resistant PM1 and CEM cells
transcribed significantly more (P=0.001) SR-B1 compared to
virus-prone Molt4 and Jurkat T cells. In regard to Huh7.5 and
HepG2 hepatoma cells, no significant difference in SR-B1
expression was found (Fig. 2B). Further, PHH expressed about
10-fold less SR-B1 mRNA than Huh7.5 cells (P=0.001) (Fig. 2B).
There also was significantly lower transcription of SR-B1 in HCV-
prone Molt4 and Jurkat cells (P=0.0001) and in primary T cells,
their subsets and PBMC (P=0.0001) than in Huh7.5 cells.
It is of note that the expression levels of house-keeping ß-actin
and HPRT genes were closely comparable in all cell types tested,
except PHH. Thus, the ß-actin mRNA levels ranged between 107
to 108 copies/mg total RNA with no statistically significant
variations. Approximately 10-fold lower transcription level was
identified in PHH (data not shown). For HPRT, highly
comparable mRNA levels were detected in all cell types examined,
including PHH (data not shown).
Expression of CLDN-1and CLDN-6 does not Coincide with
T Cells Susceptibility to HCV Infection
CLDN-1 mRNA level was found to be high in Huh7.5 cells
(361056 SEM 26104 copies/mg total RNA), while HepG2 and
PHH showed 10 to 100-fold lower copy numbers (P=0.002 and
P=0.003, respectively) (Fig. 2C). In contrast, HCV-susceptible
Molt4 and Jurkat T cells essentially did not express CLDN-1,
while PM1, but not CEM, transcribed CLDN-1 at a level greater
than 104 copies/mg total RNA. Primary T cells, their CD4+ and
CD8+ subtypes and PBMC demonstrated CLDN-1 mRNA levels
between 16102 and 1.56102 copies/mg RNA, which were
significantly lower (P=0.0001) than that detected in Huh7.5 cells
(Fig. 2C).
In regard to CLDN-6 expression, no significant (P=0.14)
difference was found between HCV-prone and resistant T cell
lines and Huh7.5 cells, while primary T cells, PBMC and PHH
tended to transcribe approximately 10-fold lower levels than
Huh7.5 cells (P=0.01) (Fig. 2D). HepG2 cells expressed the
highest (P=0.0001) levels of CLDN-6 among the cells tested.
High Expression of CD5 in Primary and Cultured T Cells
and OCLN in T Cell Lines Coincides with Permissiveness
to HCV
OCLN mRNA was expressed at high levels (105–106 copies/mg
total RNA) in Huh7.5, HepG2, PHH and HEK-293 cells, while it
was transcribed at approximately 10-fold lower (P=0.007) levels
in HCV-susceptible Molt4 and Jurkat cells (Fig. 2E). However,
HCV-resistant PM1 and CEM cells, as well as PBMC and CD4+
and CD8+ T cell subsets transcribed OCLN at levels 102–103-fold
lower (P=0.0001) than the susceptible T cell lines (Fig. 2E). The
total primary T cells demonstrated approximately 10-fold greater
expression than their subsets or total PBMC, and the reason for
this is not yet clear.
In regard to CD5, which transcription is lymphocyte restricted
and the presence of CD5 protein has been identified to be essential
for infection of T cells with HCV [25], it was confirmed that the
gene expression was significantly greater (P=0.0001) in HCV-
HCV Infection of T Lymphocytes
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prone primary T lymphocytes, their CD4+ and CD8+ subsets,
PBMC and in Molt4 and Jurkat T cell lines, as well as in HEK-
293 cells transfected with human CD5 serving as a control, than in
virus-resistant PM1 and CEM T cells (Fig. 2F). Furthermore,
PHH and HepG2 cells did not transcribe this gene, while
hepatoma Huh7.5 cells displayed CD5 mRNA at the mean level
of 9.661036 SEM 1.66103 copies/mg total RNA (Fig. 2F).
Display of CD5 and OCLN Proteins Coincides with T Cell
Permissiveness to HCV Infection
T cell lines, primary T cells, total PBMC, as well as Huh7.5 and
HepG2 cells were examined for the presence of the HCV
candidate receptor proteins by probing with appropriate anti-
bodies. In regard to SR-B1, the protein was displayed in HCV-
resistant CEM (,65% of the signal detected in Huh7.5 cells) and
PM1 (,40%), and at much lower levels in HCV-prone Molt4
(11%) and Jurkat (20%) T cells (Fig. 3A). In contrast, HepG2
displayed approximately 35% more of the protein and control
HEK-293 cells transfected with CD5 about twice less than Huh7.5
cells. These results overall well corresponded to SR-B1 mRNA
levels detected in the same cell types (Fig. 2B). Importantly,
primary T cells, their CD4+ and CD8+ subsets and total PBMC
were found to be SR-B1 protein non-reactive (Figs. 3A and 3B).
This indicated that the SR-B1 mRNA detected at levels ranging
between 103 and 104 copies/mg RNA as determined by real-time
RT-PCR (Fig. 2B) was not translated to the amounts of the protein
detectable by Western blotting (Fig. 3) or flow cytometry (data not
shown).
In regard to the TJ proteins, CLDN-1 protein was detected only
in HCV-resistant PM1 T cells (,30% of the signal displayed by
Huh7.5 cells) and in HepG2 hepatoma cells (,170% of the signal
identified in Huh7.5), and at a lower level (,25%) by control
HEK-293 cells transfected with CD5 (Figs. 3A and 3B). Notably,
primary T cells, their CD4+ and CD8+ subsets and total PBMC,
as well as HCV-prone Molt4 and Jurkat cells were entirely CLDN-
1 protein negative (Figs. 3A and 3B). This was essentially
Figure 1. Identification of HCV in T cell lines, primary T lymphocytes and PBMC. Molt4, Jurkat, PM1 and CEM T cell lines, and primary T cells
and total PBMC were exposed to plasma-derived, intact HCV and subsequently evaluated for the expression of HCV RNA positive strand by real-time
RT-PCR and HCV RNA negative strand by RT-PCR/NAH. T cell lines were analyzed at day 7 post-infection. Primary T lymphocytes and PBMC isolated
from healthy donors were exposed to the same virus as T cell lines and analyzed at day 14 post-infection, as described in Materials and Methods. (A)
Quantification of HCV RNA positive strand. Data represent means from 3 separate experiments and are presented as HCV vge (copy) per mg total RNA.
(B) Representative example of the detection of HCV RNA negative strand by RT-PCR/NAH in the cells from one of 3 experiments shown in A. Synthetic
HCV RNA positive (pos) and negative (neg) strands at 105 copies per reaction confirmed the assay specificity for detection of the virus RNA replication
strand. Water amplified in direct (DW) and nested (NW) reactions and a mock extraction served as contamination controls. The positive signals
showed the expected 244-bp oligonucleotide fragments.
doi:10.1371/journal.pone.0062159.g001
HCV Infection of T Lymphocytes
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consistent with CLDN-1 mRNA data which showed levels below
103 copies/mg total RNA in primary T cells and undetectable
levels in HCV-prone Molt4 and Jurkat T cells (Fig. 2C). On the
other hand, CLDN-6 proteins were detected in all cell types at the
levels which were comparable to those detected in Huh7.5 cells
(Fig. 3A). Again, CLDN-6 mRNA levels well corresponded to the
protein signals identified in individual cell types (Fig. 2D).
In regard to OCLN protein, HCV-susceptible Molt4 and Jurkat
cells displayed approximately 90% and 205% of the protein signal
detected in Huh7.5 cells, respectively (Fig. 3A). However, primary
T lymphocytes presented the protein at about 10-fold lower level
than Huh7.5 cells, while total PBMC were nonreactive. Further-
more, PM1 and CEM T cells exhibited trace levels of OCLN
comparing to Huh7.5, i.e., approximately 5% of the signal
detected in Huh7.5 cells (Fig. 3A). HepG2 and control CD5-
transfected HEK-293 demonstrated the protein at levels more
than 4-fold and 7-fold greater than Huh7.5 cells, respectively
(Fig. 3A). The OCLN protein signals appeared to well correspond
to the gene expression levels detected in the same cell types
(Fig. 2E).
CD5 protein was identified in HCV-susceptible Molt4 and
Jurkat T cell lines, primary total T cells and PBMC (Fig. 3A) and
in T cell subsets (Fig. 3B), and at trace levels in PM1 cell line.
Huh7.5 and HepG2 cells were CD5 protein nonreactive, while
control CD5-transfected HEK-293 cells showed the protein at
a level comparable to that detected in primary T cells and T cell
lines prone to HCV (Fig. 3A). There overall was a good agreement
between CD5 protein display and the CD5 gene expression levels.
HCV Infection Downregulates CD81 and OCLN but
Augments CD5 and does not Change SR-B1 Expression in
T Cells
Jurkat and Molt4 T cells exposed to native, patient-derived
HCV or normal human plasma (NHP) as control were cultured for
5 days and subsequently examined for expression of CD81,
OCLN, CD5 and SR-B1 by the appropriate real-time RT-PCR
assays. The result showed a significant decrease in the level of
transcription of CD81 (P=0.001) and OCLN (P=0.0008) in
HCV-infected cells comparing to those exposed to NHP, as was
illustrated for Jurkat cells in Figure 4. In contrast, CD5 mRNA
level was significantly (P=0.01) augmented in infected cells, while
that of SR-B1 remained unchanged following infection (P=0.54)
(Fig. 4). This differential effect of HCV infection on the expression
of CD81, OCLN and CD5, but not SR-B1 gene, provided
supporting evidence that the respective proteins might be engaged
in the infection process induced by HCV in T cells.
Knockdown of OCLN Expression Inhibits HCV E2
Expression in HCV-prone T Cell Line
Since the obtained data implied that OCLN may play a role in
the facilitation of HCV infection in Molt4 and Jurkat T cell lines,
although unlikely infection of primary T lymphocytes due to the
presence of this protein at a trace level in the naturally circulating
cells, the effect of the suppression of OCLN transcription on the
infectivity of intact HCV towards Jurkat cells was investigated. In
this regard, Jurkat cells were transduced with lentiviral particles
encoding different human OCLN-specific shRNA, designated as
C-1, C-2 or C-3, or with the control irrelevant shRNA, and then
exposed to infectious HCV. The results showed that the level of
OCLN expression was significantly (P=0.0001) downregulated in
OCLN-shRNA-transduced cells compared to control cells treated
Figure 2. Quantification of expression levels of the genes encoding postulated HCV receptors in T cell lines, primary T
lymphocytes, their CD4+ and CD8+ subsets, PBMC, hepatoma cell lines and human primary hepatocytes. Expression levels of: (A) CD81,
(B) SR-B1, (C) CLDN-1, (D) CLDN-6, (E) OCLN, and (F) CD5. An equivalent of 50 ng DNAse-treated RNA served as template for real-time RT-PCR
quantifications. The results represent means6SEM from 4 or more independent experiments and are presented as copies/mg total RNA.
doi:10.1371/journal.pone.0062159.g002
Figure 3. Differential display of HCV candidate receptor
proteins in HCV-prone and resistant T cell lines, primary T
lymphocytes and their subsets, PBMC, hepatoma cell lines and
control HEK-293 cells transfected with human CD5. Proteins
were separated at 25 mg per well by SDS-PAGE and after blotting
probed with appropriate antibodies. Detection of b–actin served as
a loading control. (A) Identification of SR-B1, CLDN-1, CLDN-6, OCLN,
CD5 and b–actin in the cells investigated. The level of a given protein in
a particular cell type is presented as a relative percentage of this protein
signal detected in Huh7.5 cells that was taken as 100%, except CD5
protein for which display in primary T lymphocytes was taken as 100%.
(B) Detection of SR-B1, CD5, CLDN-1 and b–actin in CD4+ and CD8+
subsets of primary T cell and in T cell lines investigated. The level of
each protein in a particular cell type was presented as a relative
percentage of the highest signal given by a given protein in any of the
cell types examined that was taken as 100%.
doi:10.1371/journal.pone.0062159.g003
HCV Infection of T Lymphocytes
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with irrelevant shRNA (Fig. 5A). It is of note that mRNA levels of
CD81 (Fig. 5B), SR-B1 (Fig. 5C) and CD5 (Fig. 5D) were not
affected by treatment with either OCLN-shRNA or irrelevant
shRNA. Further, the display of OCLN protein was inhibited by
,45% after transduction with OCLN-shRNA compared to the
control cells (Fig. 5E). Most interestingly, although the knocking
down of OCLN had no effect on the expression level of HCV
RNA positive and negative (replicative) strands detected after
exposure to virus, comparing to the control cells transduced with
irrelevant shRNA (Figs. 5F and 5G), the display of HCV E2
protein was totally inhibited in the cells treated with OCLN-
shRNA, but not in those transduced with irrelevant shRNA
(Fig. 5H). However, display of HCV NS5a protein was not
affected in cells with knockdown OCLN (Fig. 5I). This suggested
that suppression of OCLN in fact severely affected HCV synthesis
but on the posttranscriptional level likely via selectively affecting
expression of E2 protein.
Discussion
Despite that HCV is a hepatotropic virus and infection of
hepatocytes is chiefly responsible for manifestations of hepatitis C,
substantial experimental and clinical evidence indicate that HCV
replication can also be supported by cells of the immune system,
including T lymphocytes. The HCV RNA negative strand,
representing virus genome replicative intermediate, viral proteins
and virus sequences distinct from those occurring in the liver have
been identified in PBMC, T and B lymphocytes, CD4+ and CD8+
T cell subsets, and in monocytes from patients with chronic
hepatitis C (CHC) [20,21,30–35] and in persistent low-level
infection continuing after clinically apparent sustained virological
response to interferon (IFN) or IFN-ribavirin (IFN-RBV) therapy
for CHC [21,24,34,36–39]. HCV infection resulting in production
of infectious virus has also been documented in de novo infected
normal human T lymphocytes [22–24], cultured B cells [40,41],
and monocytes [20,42]. A recent study from this laboratory has
shown that naturally occurring HCV utilizes CD5, a lymphocyte
unique glycoprotein, to infect T cells [25]. As in other chronic viral
infections with noncytopathic viruses [43,44], infection by HCV of
immune privileged T cells may constitute an important mechan-
isms by which virus persists independently from its progeny
multiplying in hepatocytes. In this regard, distinct HCV variants
have been identified in the different compartments of virus
occurrence, i.e., liver and lymphomononuclear cells
[20,33,36,45,46]. Further, HCV has been occasionally detected
in circulating lymphoid cells but not in the liver, particularly in
individuals with persistent low-level (occult) infection [33,34,36]. It
has also been postulated that HCV variants inhabiting lymphoid
cells can re-infect newly transplanted livers [32,47,48]. Also, HCV
immune evasion and drug resistance might be, at least in part,
a consequence of the virus ability to protractedly replicate in the
lymphoid cell compartment, as in the case of hepatitis B virus
infection in patients on suppressive antiviral therapy [49].
The host’s factors facilitating HCV infection of human cells
were mainly investigated using HCV JFH-1 clone or HCVpp and
human hepatoma cell lines. The JFH-1-Huh7.5 model provides
a robust system in which JFH-1 HCVcc infect hepatoma Huh7.5
cells. However, these cells have a deficient innate immune
response due to the lack of RIG-I expression, perturbed signaling
and endocytic pathways, and dysfunctional mitochondria [50–55].
In addition, the genetic variance between JFH-1 clone and the
naturally occurring HCV may further affect the properties and the
nature of host factors mediating virus-cell interactions [56]. In this
context, JFH-1 fails to infect human PBMC and primary T cells
[57], which are known to be prone to infection with native HCV
in both in vivo and in vitro conditions [21–23]. As well, JFH-1
clones do not infect T cell lines which are prone to patient-derived
virus [58]. On the other hand, the authentic, patient-derived virus
does not infect Huh7.5 cells [58].
In the current study, we found that Molt4 and Jurkat cells
support HCV replication at approximately the same levels as
primary T lymphocytes after exposure to the same HCV inocula.
To recognize contribution of cellular factors to T cell susceptibility
to HCV other than CD5 and CD81, we analyzed expression of
selected HCV candidate receptors in HCV-prone and resistant T
cells, and compared their expression to that in primary T cells and
in JFH-1 strain-susceptible Huh7.5 and resistant HepG2 hepato-
ma cells. This analysis revealed that some of the postulated
hepatocyte receptors are unlikely involved in determining HCV
lymphotropism, while others may contribute to infectivity of
cancer-derived T cell lines but unlikely normal primary T cells.
Considering distribution of the proposed HCV receptors in the
lymphoid cells tested, the expression of tetraspanin CD81, which is
known to require other cellular factors to mediate HCV cell entry
[9,59], was detected at comparable levels in all lymphocytic and
non-lymphocytic cells examined, except HepG2 (see Fig. 2A).
Although CD81 likely contributes to infection of T cells, based on
Figure 4. Expression levels of CD81, OCLN, CD5 and SR-B1 in
Jurkat T cells infected with native, patient-derived HCV. Jurkat T
cells infected with plasma-derived HCV or exposed to the equivalent
amount of normal human plasma (NHP) were cultured for 5 days and
then evaluated for the expression of (A) CD81, (B) OCLN, (C) CD5 and (D)
SR-B1 by appropriate specific real-time RT-PCR assays. The results are
presented as ratios of mean copy numbers/mg total RNA from 4
independent experiments of a given gene to actin.
doi:10.1371/journal.pone.0062159.g004
HCV Infection of T Lymphocytes
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Figure 5. Effect of OCLN knockout on infection of Jurkat T cells with native, patient-derived HCV. Jurkat cells transduced with either
OCLN-specific shRNA or control irrelevant (irr) shRNA were infected with plasma-derived HCV, as described in Material and Methods. The levels of
transcription of (A) OCLN, (B) CD81, (C) SR-B1 and (D) CD5 were evaluated at day 7 post-infection using appropriate real-time RT-PCR assays. The data
are presented as mean copy numbers6SEM/mg total RNA from 2 independent experiments each evaluated in triplicate. (E) Western blot detection of
OCLN protein in Jurkat cells transduced with either irr-shRNA or OCLN shRNA. Detection of b–actin served as a loading control. The level of OCLN
protein in the cells transduced with OCLN shRNA is presented as a relative percentage of the OCLN protein signal detected in control cells that was
taken as 100%. (F) Quantification of HCV RNA positive strand in Jurkat T cells transduced with either control irr-shRNA or three separate clones of
OCLN shRNA and subsequently infected with wild-type HCV, as described in Materials and Methods. The data represent the mean copy (vge)
numbers6SEM from 2 independent experiments each evaluated in triplicate. (G) Detection of HCV RNA replicative strand in Jurkat T cells transduced
with either irr-shRNA or three different clones of OCLN shRNA (C1–C3) and infected with HCV, as indicated in (F). Synthetic HCV RNA positive (pos)
and negative (neg) strands at 105 copies/reaction served as the assay specific controls. DW, NW and a mock as described in the legend to Figure 1. (H)
Detection of HCV E2 protein by Western blotting in Jurkat T cells transduced with irr-shRNA or with three OCLN shRNA clones (C1–C3) and then
infected with HCV. Huh7 cells expressing HCV AB12-A2FL replicon and naı¨ve Huh7 cells served as HCV E2 positive and negative controls, respectively.
Detection of b-actin served as a loading control. (I) Detection of HCV NS5a protein by confocal microscopy in HCV infected Jurkat transduced with
C1encoding OCLN-specific shRNA (C1) and in intact (untransduced) Jurkat cells infected with the same virus as a positive staining control. HCV-
infected Jurkat transduced with C1 clone exposed to isotype antibody control instead of anti-NS5a served as a negative control. The cells were
counterstained with DAPI to identify nuclei and examined under transmitted light (TL). The images were captured at X60 magnification.
doi:10.1371/journal.pone.0062159.g005
HCV Infection of T Lymphocytes
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the fact that antibodies against CD81 inhibited infection of
primary T cells as well as Molt4 and Jurkat cells with native virus
[23,25], CD81 molecule is not the limiting factor of the infection
since HCV-resistant PM1 and CEM T cells express CD81 at
similar levels to cells prone to this virus (see Fig. 2A).
Another candidate receptor, SR-B1, is expressed at high levels
in liver tissue and is considered an important HCV entry factor, as
studies using soluble HCV E2 protein and HepG2 cells lacking
CD81, but expressing SR-B1, showed. This interaction was found
to be highly selective since neither mouse SR-BI nor the closely
related human scavenger receptor CD36 was able to bind E2 [60].
However, although antibodies to SR-B1 markedly inhibited the
binding of E2 protein or HCV-like particles to primary tupaia
hepatocytes, they were not able to block infection with native,
plasma-derived HCV [61]. Considering lymphocytes, a significant-
ly (P=0.007) lower expression of SR-B1 was detected in primary
T cells, their CD4+ and CD8+ subsets and total PBMC than in T
cell lines and Huh7.5, HepG2 and PHH. Moreover, HCV-
resistant PM1 and CEM cells expressed significantly (P=0.001)
more SR-B1 than HCV-susceptible Molt4 and Jurkat T cells. In
consequence, despite being susceptible to HCV, primary T cells,
their subsets and PBMC did not display SR-B1 protein; therefore,
the contribution of this protein to HCV lymphotropism can be
with a high certainty excluded. This finding appears to be
comparable to that reported by others where the interaction
between soluble truncated HCV E2 protein and PBMC, B cells,
monocytes or dendritic cells as targets was tested [62]. Taken
together, the data indicate that while CD81 is likely involved in
recognition of the host’s T cells by HCV, SR-B1 is not
contributing to this process.
Although a pivotal contribution of CD5 to T cell tropism of
HCV has been previously delineated [25], we re-analyzed
expression of CD5 in the context of other HCV candidate
receptors in the new set of experiments performed for the purpose
of the current study. In general, the obtained data remained in
agreement with those reported and confirmed that CD5 gene
expression occurred at significantly (P=0.0001) greater levels in
HCV-susceptible than resistant T cells. This difference coincided
with the detection of CD5 protein in HCV-prone but not in HCV-
resistant T cells. In contrast to T cells, Huh7.5 and HepG2 cells
did not display CD5 protein, as reported [25].
A role for TJ proteins in determining permissiveness of
lymphoid cells to HCV remained uncertain. We compared the
levels of CLDN-1, CLDN-6 and OCLN mRNAs and respective
proteins in the cell types examined. CLDN-1, a protein previously
reported to be an HCV entry factor mediating infection of hepatic
cells, as it has been determined by examining interactions between
HCVpp and HCVcc preparations and Huh7.5 cells [14], was
expressed only by hepatoma cells and by lymphoma-derived PM1
T cells, which are resistant to HCV infection unless activated [25].
Unlike reported [14], HEK-293 cells were found to be CLDN-1
reactive, which might be due to a different cell clone or our more
sensitive method of this protein detection. Thus, our results clearly
showed that CLDN-1 is not involved in determining permissive-
ness of primary T lymphocytes to HCV. Further, CLDN-6 mRNA
and its protein were identified at comparable levels in both HCV-
susceptible and resistant cells, making their contribution to HCV
infectivity of T lymphocytes also unlikely. In this regard, others
have shown that human PBMC transcribe CLDN-6 but not
CLDN-1 and that human hepatoma Bel7402 cell line was
recognized by HCVpp despite that the cells did not express
CLDN-1 [63]. This may suggest that CLDN-1 might be
dispensable for infection of not only lymphocytes but also some
non-lymphoid cells.
OCLN, which is another member of the TJ protein family,
was shown to mediate infection of Huh7.5 cells by HCVcc and
to be likely involved at the later stages of HCV entry [15].
Although OCLN expression was found to be significantly higher
in hepatic cells, its mRNA and protein were detected in HCV-
prone Molt4 and Jurkat T cells at much greater levels than in
primary T cells and PBMC. To confirm potential relevance of
OCLN to the facilitation or maintenance of HCV infection in
virus-susceptible T cell lines, the effect of OCLN-knockout on
the level of HCV replication in Jurkat T cells was investigated.
While both HCV RNA positive and negative (replicative)
strands were detected at comparable levels in the cells
transduced with OCLN-shRNA or irrelevant-shRNA, virus E2
protein was detected only in the control cells treated with
irrelevant-shRNA. This observation appears to be compatible to
the previous report which showed no effect of OCLN silencing
on the HCV RNA level in Huh7 cells carrying genomic or
subgenomic HCV replicons [15]. In contrast to E2 protein, the
display of HCV NS5a protein was not affected by knocking
down of OCLN. The reason why HCV E2 protein, but not
virus NS5a protein, was absent in the cells with silenced OCLN
is not clear. It might be due to the interaction between E2 and
OCLN and to the hypothetical possibility that OCLN facilitates
translocation of the E2 protein to the appropriate intracellular
compartment and/or prevents its premature release from the
infected cell. In this regard, HCV E2 and OCLN have been
found to co-localize in hepatocyte endoplasmic reticulum and
co-immunoprecipitate [64]. Overall, the obtained data suggest
that OCLN can selectively affect on the posttranscriptional level
the HCV E2 protein expression in an infected T cell line.
However, since OCLN protein was displayed at very low levels
in primary T cells and not at all in PBMC, it may play
a negligible role, if any, in HCV infectivity towards T cells
in vivo.
In agreement with the previous findings showing downregulated
expression of OCLN and CLDN-1 in Huh7 cells after infection
with JFH-1 HCVcc [65], the level of OCLN and CD81 expression
significantly decreased in Jurkat T cells infected with native HCV.
Meanwhile, the transcription of CD5 became augmented and that
of SR-B1 unchanged. These findings can be interpreted as an
indication that HCV downregulates the display of OCLN and
CD81 to prevent superinfection, as it has been postulated before
[65]. This also provides supplementary evidence for the impor-
tance of these molecules in HCV infection of lymphocytes, at least
in the case of the virus-susceptible T cell lines. On the other hand,
upregulation of CD5 expression may protect cells from apoptosis
and allow for more prolonged and robust HCV replication in the
cells infected [66–68]. Further investigations will be required to
assess validity of these hypotheses.
The data obtained in this study contribute to the better
understanding of the nature of HCV lymphotropism, which
remains a vaguely recognized property of naturally propagating
virus. Overall, they are consistent with the notion that HCV
utilizes a distinct set of cellular molecules to gain entry into human
lymphocytes in comparison to that expected to mediate HCV
tropism towards human hepatocytes. Among the molecules
analyzed, only expression of CD5 is uniquely restricted to
lymphocytes, implying a central role of this glycoprotein in
HCV lymphotropism. However, no association between expres-
sion of SR-B1 or CLDN-1 and the susceptibility of T cells to
infection with native HCV was found, while contribution of CD81
as a potential co-receptor was confirmed. Considering a surpris-
ingly large number of cellular molecules implicated in HCV entry
to hepatocytes, it cannot be excluded that yet other, not yet
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identified factors, are involved in the HCV tropism towards cells
constituting the immune system.
Materials and Methods
Cell Lines, Primary Cells and Culture Conditions
Molt4 (CRL-1582) and Jurkat (TIB-152) T cell lines were
provided by the American Type Culture Collection (ATCC,
Manassas, Virginia, USA). PM1 cells were acquired from the
National Institutes of Health AIDS Research and Reference
Program (Rockville, Maryland, USA) and CCRF-CEM cells
(CEM, ACC-240) from the Deutsche Sammlung von Mikroorga-
nismen und Zellkulturen GmbH (Braunschweig, Germany).
Molt4, Jurkat and CEM cell lines were originally derived from
patients with acute T lymphoblastic leukemia [69], while PM1
from a patient with acute cutaneous T cell lymphoma [70]. The
cells were cultured at 16105 cells/well in 5 ml of medium
containing RPMI 1640 supplemented with 10% heat-inactivated
fetal calf serum (FCS), 2 mM glutamine and 0.1 mM nonessential
amino acids (Invitrogen Life Technologies, Burlington, Ontario,
Canada). In some experiments, the cells were stimulated for 72 h
with phorbol myristate acetate (PMA; Sigma-Aldrich, Oakville,
Ontario, Canada) at 50 ng/ml in the presence of 500 ng/ml
ionomycin (Sigma-Aldich), as reported [25].
Total PBMC were isolated from two healthy donors by gradient
centrifugation in Ficoll-HyPaque (Pharmacia Biotech Inc., Baie-
D’Urfe´, Quebec, Canada) [37]. Primary T lymphocytes were
affinity-purified from monocyte-depleted PBMC by negative
selection using MACS magnetic microbeads (Miltenyi Biotec,
Auburn, California, USA), as reported [25,39]. CD4+ and CD8+
T cell subsets were isolated from PBMC by affinity chromatog-
raphy using AutoMacs Pro-Separator system (Miltenyi Biotec)
following the manufacturer’s instruction. T cells and their subsets
were 97–98% pure by flow cytometry analysis. For some
experiments, PBMC and affinity-purified primary T cells were
stimulated with 5 mg/ml phytophemagglutinin (PHA; Sigma-
Aldrich) in the presence of 20 IU/ml human recombinant
interleukin-2 (IL-2; Roche Molecular Diagnostics, Pleasanton,
California, USA), as described [21,37].
HCV replicon AB12-A2FL Huh7 cell line, containing full-
length HCV genotype 1b, was provided by Drs Christopher
Richardson and Joyce Wilson formerly from Ontario Cancer
Institute, University of Toronto, Canada. The human hepatoma
Huh7.5 cells were provided by Dr. Takaji Wakita from National
Institute of Infectious Diseases, Shinjuku, Japan and Dr. Rodney
Russell from Memorial University of Newfoundland, St. John’s,
NL Canada. Human hepatoma HepG2 (HB-8065) and human
embryonic kidney 293 fibroblasts (HEK-293; CRL-1573) cell lines
were supplied by ATCC. The cells were maintained in DMEM
medium supplemented with 10% FCS. PHH isolated by
microperfusion of a healthy portion of the liver of a 58-year old
male donor were purchased from Dominion Pharmakine (Derio-
Bizkaia, Spain) [71].
HCV Infection Assay
Cultured T cell lines, either intact or stimulated with PMA/
ionomycin for 72 h at 16105 cells/well, supplemented with 2 ml
of culture medium in 6-well plates were exposed for 24 h to
,16105 virus genome copies (virus genome equivalents, vge) of
HCV genotype 1a-positive plasma pool prepared from patients
with CHC who were antiviral treatment naive. Infectivity of the
pool was established in preliminary experiments using Molt4 and
Jurkat T cell lines and PHA-stimulated primary T lymphocytes, as
previously reported [23,25]. Cells exposed under identical
conditions to an equivalent volume of NHP served as negative
controls. After exposure to HCV or NHP, the cells were
extensively washed, suspended in fresh culture medium and
cultured for 4–7 days post-infection (d.p.i.), as reported [25]. The
study protocol was approved by the local Human Investigation
Committee.
Silencing of OCLN by RNA Interference
Lentiviral transduction particles encoding different human
OCLN-specific shRNA (clones: TRCN0000158463,
TRCN0000158804, TRCN0000159413, TRCN0000159613
and TRCN0000159771; designated as C-1 to C-5) with a titer
between 2.96107 and 3.96107 infectious virus and 4.66107 non-
target control transduction particles (#SHC001V; designated as
irr) were prepared by Sigma-Aldrich. 16103 Jurkat cells in 100 ml
RPMI 1640 medium was transduced at 4 multiplicity of infection
(MOI) in 96-well plates in the presence of 2.5 mg/ml polybrene
(Sigma-Aldrich). Cells were spun down at 4uC for 10 min at
2,000 rpm, incubated at 37uC for 24 h, and allowed to revive in
fresh medium for another 24 h. Transduced Jurkat cells were
selected in the presence of 2 mg/ml puromycin (Sigma-Aldrich) for
7 days. The level of OCLN expression was determined by real-
time RT-PCR and Western blotting (see below). Only C-1, C-2
and C-3 were used in subsequent experiments, since C-4 and C-5
were found to be toxic to Jurkat T cells. Subsequently, Jurkat cells
transduced with C-1, C-2 or C-3 or with the control scrambled
shRNA, and the nontransduced cells were used as targets in HCV
infection following the procedure described above.
RNA and Transcription to cDNA
Total RNA was extracted using Trizol (Invitrogen Life
Technologies, Burlington, Ontario, Canada). RNA used for
quantification of cellular genes was treated with DNAse, as
reported [38]. cDNA was transcribed with Moloney murine
leukemia virus reverse transcriptase (RT) (Invitrogen), as pre-
viously described [25,37].
Detection of HCV
HCV RNA positive and negative (replicative) strands were
identified using cDNA derived from 1 or 2 mg and 2 or 3 mg,
respectively, of total RNA and the strand-specific amplification
conditions reported in detail previously [25,37]. The specificity of
the signal detection and validity of controls were routinely
confirmed by nucleic acid hybridization (NAH) with 32P-labeled
recombinant HCV 59-untranslated region-E2 fragment (rHCV
UTR-E2) as a probe [37]. The sensitivity of RT-PCR/NAH assay
for HCV RNA-positive strand identification was ,10 vge/ml
(,2 IU/ml) or ,5 vge/mg of total RNA, while that for HCV
RNA-negative strand was 25–50 vge/mg of total RNA, as reported
[25,37].
Cloning of SR-B1 and TJ Gene Sequences
To facilitate quantification of the expression levels of SR-B1 and
TJ genes in the cells examined, cDNA transcribed from human
PBMC or liver was amplified by PCR with primers shown in
Table 1. Amplified fragments were cloned into the dual promoter
vector PCRII using the TOPO TA cloning system (Invitrogen)
and then excised and sequenced in both directions to confirm the
gene specificity. The cloned fragments were used as quantitative
and the sensitivity standards in real-time RT-PCR assays. Human
CD5 and CD81 gene fragments were generated in the previous
study [25].
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Real-time RT-PCR
The expression of SR-B1, CLDN-1, CLDN-6, OCLN, CD81
and CD5 was quantified by specific real-time RT-PCR assays
during 40 cycles using the LightCycler 480 (Roche Diagnostics,
Mannheim, Germany). Reactions were performed in 10-mL
volumes, each containing 2 mL cDNA derived from 50 ng
DNAse-treated RNA using primer pairs shown in Table 1.
Annealing temperature of 56uC were used for amplification of
OCLN, CD81, b-actin and hypoxanthine phosphoribosyltransfer-
ase (HPRT), while 60uC annealing temperature for amplification
of SR-B1, CLDN-1, CLDN-6 and CD5. Expression of genes of
interest was evaluated in samples obtained from at least 4 separate
experiments. b-actin and HPRT were used as loading controls.
The sensitivity of the real-time RT-PCR assays was determined
using 10-fold, serial dilutions of the cloned fragments of the
respective genes and was found to be between 10 to 102 copies/
reaction. In regard to HCV RNA positive strand quantification,
the copy numbers were enumerated by real-time RT-PCR using
10-fold serial dilution of rHCV UTR-E2, as described previously
[21].
Western Blotting
Cells were treated with ice-cold RIPA buffer (1% NP-40, 0.5%
DOC, 0.1% SDS, 150 mmol/L NaCl in 50 mmol/L Tris,
pH 8.0; Sigma-Aldrich) and cellular debris removed by centrifu-
gation. Proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) at 25 mg protein
per lane and then blotted onto a nitrocellulose membrane
(Amersham Biosciences, Piscataway, New Jersey, USA) by wet
transfer using the Bio-Rad SD cell system (Bio-Rad Laboratories,
Mississauga, Ontario, Canada) [72]. The blots were incubated
with 5% skimmed milk in Tris-buffered saline, pH 7.4, for 1 h at
room temperature and exposed overnight at 4uC to working
dilutions of appropriate antibodies diluted in the same blocking
buffer. Mouse monoclonal antibodies (mAb) to SR-B1 (clone 25/
CLA-1) and OCLN (clone 19) were purchased from B.D.
Biosciences (Mississauga, Ontario, Canada), rabbit antibodies to
CLDN-1 were from Invitrogen, while rabbit antibodies to CLDN-
6 (ab75055) and CD5 (ab52964) were acquired from Abcam Inc.
(Cambridge, Massachusetts, USA). In some instances, the presence
of HCV envelope protein in infected lymphocytes and in control
AB12-A2FL Huh7 cells was detected with anti-E2 mouse mAb
provided by Dr. Arvind Patel, University of Glasgow, Glasgow,
United Kingdom, as reported [25]. Detection of b-actin with
specific rabbit mAb (Sigma-Aldrich) served as protein loading
control. Reactions were developed with horseradish peroxidase-
conjugated goat anti-rabbit or goat anti-mouse IgG F(ab’)2
antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania,
USA) and visualized using an ECL detection kit (Sigma-Aldrich).
Protein signals were quantified by densitometry using the
computer-assisted image processing application ImageJ from the
National Institute of Health [73]. For comparative evaluations, the
density of the protein signals detected in Huh7.5 cells were taken
as 100%, except for CD5 protein for which the signal detected in
primary T cells was used as 100% or unless otherwise indicated.
Confocal Microscopy
To detect HCV NS5a protein, cells were fixed with 2%
paraformaldehyde, permeabilized with 0.25% saponin, and then
exposed to either mouse anti-HCV NS5a mAb (Chemicon
International, Temecula, California, USA) or appropriate isotype
mAb control (BD Biosciences) overnight at 4uC, washed and then
exposed to Cy2-labeled donkey anti-mouse antibody (Jackson
ImmunoResearch) on ice for 60 min. Subsequent washing and
counterstaining with 49,6-diamidino-2-phenylindole (DAPI;
0.1 mg/ml) (Sigma-Aldrich) were done and slides were examined
under an Olympus BX50WI microscope with a FlouView FV300
confocal system (Olympus America Inc., Melville, New York
State, USA) as previously reported [25].
Statistical Analyses
Results were analyzed by a one way analysis of variance or
unpaired Student t test with Welch’s correction using GraphPad
Prism software (GraphPad Software, Inc., San Diego, California,
USA). Differences between experimental conditions were consid-
ered to be significant when two-sided P values were below or equal
to 0.05.
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